NasdaqGS:LABLife Sciences
Standard BioTools (LAB) Q4 Profit Challenges Longstanding Unprofitable Narrative
Standard BioTools (LAB) has posted a mixed set of FY 2025 numbers, with Q4 revenue at US$23.8 million and basic EPS of US$0.04, even as trailing twelve month figures still show a loss with EPS at US$0.15 and net income from continuing operations at a loss of US$58.8 million. The company has seen quarterly revenue range from US$19.6 million to US$23.8 million across 2025, while basic EPS has moved between a loss of US$0.08 in Q3 and a small profit of US$0.04 in Q4. This sets up a story where...